Study Summary
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
NKG2D-based CAR T-cellsBIOLOGICAL
Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Xunyang Changchun Shihua Hospital | Jiujiang | Jiangxi | China |